Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 61, Issue 3, Pages 423-426Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.119.230979
Keywords
nAChR; cholinergic; F-18-ASEM; dementia; PET
Funding
- Henry N. Wagner, Jr., Endowment
- Johns Hopkins Doris Duke Foundation Early Clinician Investigator Award
- Johns Hopkins Alzheimer Disease Research Center [P50 AG005146]
Ask authors/readers for more resources
Emerging evidence supports a hypothesized role for the alpha 7-nicotinic acetylcholine receptor (alpha 7-nAChR) in the pathophysiology of Alzheimer's disease. F-18-ASEM (3-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-6-F-18-fluorodibenzo[b,d]thiophene 5,5-dioxide) is a radioligand for estimating the availability of alpha 7-nAChR in the brain in vivo with PET. Methods: In this cross-sectional study, 14 patients with mild cognitive impairment (MCI), a prodromal stage to dementia, and 17 cognitively intact, elderly controls completed F-18-ASEM PET. For each participant, binding in each region of interest was estimated using Logan graphical analysis with a metabolite-corrected arterial input function. Results: Higher F-18-ASEM binding was observed in MCI patients than in controls across all regions, supporting higher availability of alpha 7-nAChR in MCI. F-18-ASEM binding was not associated with verbal memory in this small MCI sample. Conclusion: These data support use of F-18-ASEM PET to examine further the relationship between alpha 7-nAChR availability and MCI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available